A small trial evaluated the efficacy of lactoferrin supplementation (250 mg, three times/day for 30 days) as a treatment for self-reported dysgeusia in 12 cancer patients (four with BC), who had developed self-reported taste and smell alterations after receiving CT compared with 12 healthy controls [78], showing a significant reduction in the scores for dysgeusia (2.0 points reduction of a score 0–10 based on nine questions on taste changes, p = 0.02) with respect to baseline at 30-day post-supplementation. The gene discussed is LTF; the disease is breast cancer.